Evidence map›Paper›PMID 31578436›Full record

ArticleScientific reports2019

Assessing trends of breast cancer and carcinoma in situ to monitor screening policies in developing settings.

Érika de Abreu Costa Brito, Marcela Sampaio Lima, Hianga Fayssa Fernandes Siqueira, Adriane Dórea Marques, Alex Rodrigues Moura, Evânia Curvelo Hora, Carlos Anselmo Lima, Marceli de Oliveira Santos, Mirian Carvalho de Souza, Angela Maria da Silva and 2 more

Abstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Érika de Abreu Costa BritoHealth Sciences Graduate Program, Aracaju, Sergipe, Brazil.
Marcela Sampaio LimaHealth Sciences Graduate Program, Aracaju, Sergipe, Brazil.
Hianga Fayssa Fernandes SiqueiraHealth Sciences Graduate Program, Aracaju, Sergipe, Brazil.
Adriane Dórea MarquesHealth Sciences Graduate Program, Aracaju, Sergipe, Brazil.
Alex Rodrigues MouraHealth Sciences Graduate Program, Aracaju, Sergipe, Brazil.
Evânia Curvelo HoraHealth Sciences Graduate Program, Aracaju, Sergipe, Brazil.
Carlos Anselmo LimaAracaju Cancer Registry, Aracaju, Sergipe, Brazil. carlos.a.lima@ufs.br.ORCID http://orcid.org/0000-0003-4269-7320
Marceli de Oliveira SantosCONPREV/Brazilian National Cancer Institute, Rio de Janeiro, Brazil.ORCID http://orcid.org/0000-0001-5197-2019
Mirian Carvalho de SouzaCONPREV/Brazilian National Cancer Institute, Rio de Janeiro, Brazil.
Angela Maria da SilvaHealth Sciences Graduate Program, Aracaju, Sergipe, Brazil.
Hugo Leite de Farias BritoHealth Sciences Graduate Program, Aracaju, Sergipe, Brazil.
Rosana CipolottiHealth Sciences Graduate Program, Aracaju, Sergipe, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There have been arguments about the role of breast cancer screening at the population level, and some points of controversy have arisen, such the establishment of organized screening policies and the age at which to begin screening. The real benefit of screening has been questioned because the results of this practice may increase the diagnosis of indolent lesions without decreasing mortality due to breast cancer. The authors have proposed a study of incidence and mortality trends for breast cancer in a developing setting in Brazil to monitor the effectiveness of the official recommendations that prioritize the age group from 50 to 69 years. The database of the Cancer Registry and the Mortality Information System was used to calculate age-standardized and age-specific rates, which were then used to calculate incidence and mortality trends using the Joinpoint Regression Program. The results showed stability in trends across all ages and age-specific groups in both incidence and mortality. In conclusion, we found that incidence and mortality rates are compatible with those in regions with similar human development indexes, and trends have demonstrated stabilization. Thus, we do not endorse changes in the official recommendations to conduct screening for ages other than 50 to 69 years, nor should policy makers implement organized screening strategies.

Indexed as

Health PolicyAdultAgedAge FactorsBrazilBreast Carcinoma In SituBreast NeoplasmsDeveloping CountriesEarly Detection of CancerFemaleHumansMiddle AgedMortalityPractice Guidelines as Topic

Identifiers

PMID31578436
PMCPMC6775160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.